Uploaded October 2024 | Updated September 2026, 1 hour ago

---

The Calibr-Skaggs Institute, part of Scripps Research, has begun testing a new regenerative lung therapy called CMR316. This inhaled treatment could change the way we treat lung diseases like idiopathic pulmonary fibrosis (IPF) and potentially even chronic obstructive pulmonary disease (COPD) by stimulating stem cells to restore damaged lung tissue. In this phase 1 clinical trial, they're checking the safety and effects of this once-weekly drug in both healthy volunteers and IPF patients.

For more information on CMR316 and the trial, visit:
https://www.scripps.edu/